• 首页
  • 创刊词
  • 期刊介绍
    • 杂志简介
    • 编委会
    • 编辑部
  • 过刊浏览
  • 杂志订阅
    • 订阅须知
    • 在线订阅
  • 在线投稿
    • 投稿指南
    • 年度选题
    • 在线投稿
  • 下载中心
  • 学术交流
    • 研究论坛
    • 学术沙龙
    • 编委会会议
  • 登录
    • 作者登录
    • 审稿登录
    • 编辑登录
    • 读者登录
引用本文:韩雨倍, 刘文臣, 陈琛, 杨才君, 方宇.2023年版WHO基本药物示范目录特点分析及启示[J].中国卫生政策研究,2024,17(2):53-58
2023年版WHO基本药物示范目录特点分析及启示
投稿时间:2023-11-01  修订日期:2024-01-11  PDF全文浏览  HTML全文浏览
韩雨倍1,2, 刘文臣1,2, 陈琛1,2, 杨才君1,2, 方宇1,2
1. 西安交通大学药学院 陕西西安 710061;
2. 西安交通大学药品安全与政策研究中心 陕西西安 710061
摘要:对2023年版世界卫生组织的基本药物示范目录(第23版)与儿童基本药物示范目录(第9版)进行分析,首先梳理目录调整的工作流程与递交申请所需的材料;接着归纳新版目录的调整依据和特点,目录内的药物数量创历史新高、广泛纳入创新药、审慎遴选儿童药、重视临床获益证据与公共卫生可负担性。建议参考WHO经验,结合国情尽快对我国基本药物目录进行更新,注意基药目录与医保目录的区别与联系,做好目录衔接,满足基本用药需求,确保药品可及性,优化卫生资源配置。
关键词:世界卫生组织  基本药物示范目录  遴选程序  循证依据  医保目录
The characteristics and implication of WHO Essential Medicines Model List 2023
HAN Yu-bei1,2, LIU Wen-chen1,2, CHEN Chen1,2, YANG Cai-jun1,2, FANG Yu1,2
1. School of Pharmacy, Xi’an Jiaotong University, Xi’an Shaanxi 710061, China;
2. Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an Shaanxi 710061, China
Abstract:The present analysis was based on the iteration of the 2023 WHO Essential Medicines Model List (23rd list) and Essential Medicines Model List for Children (9th list). In a methodological fashion, the adjustment procedure of the basic drug list and the materials required to submit the application were sorted out. Subsequently, a comprehensive synthesis of predominant features characterizing the 2023 edition of the EML and EMLc are summarized (offered). Notably, this edition boasts the highest count of medicines ever included featuring extensive inclusion of innovative drugs to fill the gap, select medicines for children carefully, and the emphasizing on clinical benefit evidence and public health affordability. It is suggested that China should update the NEML according to the national conditions and the experience of WHO as soon as possible, pay attention to the difference and connection between the list of essential medicines and the list of medical insurance, and play a meticulous role for establishing effective linkages between two lists. Such measures are envisaged to meet the basic drug needs, and ensure the accessibility and affordability of drugs, thereby optimizing the allocation of health resources.
Key words:World Health Organization  Essential medicines model list  Selection procedure  Evidence-based reference  Medical insurance drug reimbursement list
摘要点击次数: 1053    全文下载次数: 320
版权所有:《中国卫生政策研究》编辑部
您是本站第62142963位读者 今日访问354次
京ICP备10218182号-6

京公网安备 11010502037852号